Develops antibodies for Alzheimer's and cancer diseases.
Dec 2024Revenue $601K/yrExpenses $19.3M/yr
No trendCash runway ≈ 1 month from Dec 2024
Figures by year
When will Vaccinex be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2024, revenue was $601K and expenses $19.3M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2024 | $601K | $19.3M | −$18.7M |
| Dec 2023 | $570K | $23.5M | −$22.9M |
| Dec 2022 | $275K | $20.2M | −$19.9M |
| Dec 2021 | $900K | $23.4M | −$22.5M |
| Dec 2020 | $625K | $29.0M | −$28.3M |
| Dec 2019 | $523K | $32.5M | −$32.0M |
| Dec 2018 | $724K | $28.0M | −$27.3M |
| Dec 2017 | $90.0K | $21.2M | −$21.1M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.